Clinical Drug Experience Knowledgebase

hydroxychloroquine (plaquenil) (1 trial)

insulin glargine (toujeo) (1 trial)

insulin human (humulin) (1 trial)

rimabotulinumtoxinB (Myobloc) (1 trial)

sodium chloride (1 trial)

vitamin c (1 trial)

ziprasidone (geodon) (1 trial)

bnt162b2 (Comirnaty) (1 trial)

corticotropin (acthar) (1 trial)

mrna-1273 (Spikevax) (1 trial)

aldesleukin (Proleukin) (3 trials)

anti-kras g12v mtcr (1 trial)

anti-ox40 (5 trials)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

bavituximab (1 trial)

belapectin (3 trials)

bevacizumab (avastin) (2 trials)

bicalutamide (casodex) (1 trial)

binimetinib (mektovi) (1 trial)

bortezomib (velcade) (1 trial)

capecitabine (xeloda) (2 trials)

cd25-depleted peripheral blood mononuclear cell (1 trial)

cisplatin (platinol) (1 trial)

cyclophosphamide (cytoxan) (8 trials)

docetaxel (taxotere) (3 trials)

dribbles (3 trials)

durvalumab (imfinzi) (2 trials)

encorafenib (braftovi) (1 trial)

fludarabine (fludara) (2 trials)

fluorouracil (efudex) (1 trial)

galunisertib (1 trial)

gemcitabine (gemzar) (4 trials)

gp-100 peptide vaccine (3 trials)

gvax pancreatic cancer vaccine (1 trial)

human papillomavirus 16 monovalent (2 trials)

human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil) (1 trial)

imiquimod (aldara) (2 trials)

immune globulin (human) (Gamastan) (1 trial)

ipilimumab (yervoy) (5 trials)

irx-2 (1 trial)

ixabepilone (ixempra) (1 trial)

lenvatinib (lenvima) (1 trial)

medi0680 (1 trial)

medi-6469 (2 trials)

nivolumab (opdivo) (4 trials)

paclitaxel (taxol) (2 trials)

pembrolizumab (keytruda) (10 trials)

peripheral blood lymphocytes (1 trial)

rituximab (rituxan) (1 trial)

sargramostim (leukine) (3 trials)

tucatinib (Tukysa) (1 trial)

abiraterone (zytiga) (1 trial)

alpha-tea (1 trial)

autologous hematopoietic stem cells (1 trial)

bacille calmette-guerin (1 trial)

cabozantinib (cometriq) (1 trial)

carboplatin (paraplatin) (1 trial)

carboxyamidotriazole orotate (1 trial)

cavatak (1 trial)

cd80 breast cancer vaccine (1 trial)

cdx-1140 (2 trials)

corvax (1 trial)

dpv-001 (1 trial)

dpx-survivac (1 trial)

everolimus (zortress) (1 trial)

grn-1201 (1 trial)

gv 1001 (1 trial)

incagn01876 (1 trial)

incmga00012 (1 trial)

incomplete freund's adjuvant (1 trial)

indomethacin (indocin) (1 trial)

keyhole limpet hemocyanin (2 trials)

letrozole (femara) (1 trial)

melatonin (1 trial)

moxifloxacin (avelox) (1 trial)

multivitamins (1 trial)

omeprazole (prilosec) (1 trial)

pemetrexed (alimta) (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

sulfamethoxazole (gantanol) (1 trial)

tadalafil (cialis) (2 trials)

tavokinogene telseplasmid (1 trial)

temozolomide (temodar) (2 trials)

tetanus toxoid (1 trial)

trimethoprim (1 trial)

tsa-reactive tcr-engineered t cells (2 trials)

xoma 358 (1 trial)

calcium (1 trial)

candesartan (atacand) (1 trial)

colchicine (colbenemid) (1 trial)

herv-e tcr transduced cd8+/cd34+ t cells in hlaa* 11:01 positive patients (1 trial)

pamidronate (aredia) (1 trial)

vitamin d3 (1 trial)